Mirogabalin besylate is primarily used in the treatment of neuropathic pain, particularly in conditions such as diabetic peripheral neuropathy and postherpetic neuralgia. It functions by selectively binding to the α2δ subunit of voltage-gated calcium channels in the central nervous system, which helps reduce the release of neurotransmitters involved in pain signaling. This mechanism provides effective pain relief with a favorable tolerability profile. It is often prescribed when other pain management therapies have proven insufficient or caused undesirable side effects. Additionally, its pharmacokinetic properties allow for convenient once-daily dosing, improving patient adherence to treatment regimens.